Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Shares Issued (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Shares Issued for 6 consecutive years, with $73000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Shares Issued rose 392.0% to $73000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $73000.0, a 14.06% increase, with the full-year FY2025 number at $73000.0, up 14.06% from a year prior.
  • Shares Issued was $73000.0 for Q4 2025 at Lexicon Pharmaceuticals, up from -$25000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $139.0 million in Q2 2023 to a low of -$276000.0 in Q3 2023.
  • A 3-year average of $39.7 million and a median of $73000.0 in 2025 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: plummeted 100.02% in 2024, then surged 392.0% in 2025.
  • Lexicon Pharmaceuticals' Shares Issued stood at $138.8 million in 2023, then plummeted by 100.02% to -$25000.0 in 2024, then soared by 392.0% to $73000.0 in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Shares Issued are $73000.0 (Q4 2025), -$25000.0 (Q4 2024), and $1000.0 (Q2 2024).